Amgen Inc. (AMGN): Price and Financial Metrics


Amgen Inc. (AMGN)

Today's Latest Price: $224.13 USD

0.68 (-0.30%)

Updated May 28 6:55pm

Add AMGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

AMGN Stock Summary

  • AMGN has a market capitalization of $131,843,889,538 -- more than approximately 98.81% of US stocks.
  • AMGN's went public 34.43 years ago, making it older than 92.87% of listed US stocks we're tracking.
  • In terms of volatility of its share price, AMGN is more volatile than merely 4.09% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Amgen Inc are ABBV, AZN, LLY, SNY, and BMY.
  • AMGN's SEC filings can be seen here. And to visit Amgen Inc's official web site, go to www.amgen.com.
AMGN Daily Price Range
AMGN 52-Week Price Range

AMGN Stock Price Chart More Charts


AMGN Price/Volume Stats

Current price $224.13 52-week high $244.99
Prev. close $224.81 52-week low $166.68
Day low $222.25 Volume 2,591,000
Day high $226.62 Avg. volume 3,082,661
50-day MA $222.27 Dividend yield 2.86%
200-day MA $218.03 Market Cap 131.84B

Amgen Inc. (AMGN) Company Bio


Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.

AMGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$224.13$192.08-15%

Below please find a table outlining a discounted cash flow forecast for AMGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amgen Inc ranked in the 44th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Amgen Inc, consider:

  • AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 27.38% of tickers in our DCF set.
  • The weighted average cost of capital for the company is 7. This value is greater than only 13.48% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-16%
1%-15%
2%-15%
3%-14%
4%-13%
5%-12%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMGN, try FONR, HNGR, CRL, DGX, and STE.


AMGN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AMGN Latest Social Stream


Loading social stream, please wait...

View Full AMGN Social Stream

Latest AMGN News From Around the Web

Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.

Hedge Funds Started Cashing Out Of Amgen, Inc. (AMGN)

In this article we will check out the progression of hedge fund sentiment towards Amgen, Inc. (NASDAQ:AMGN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]

Yahoo | May 27, 2020

Amgen To Webcast Investor Meeting At 56th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29, at 1:00 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate to discuss Amgen's oncology program, including data being presented on the Company's KRASG12C inhibitor sotorasib.

Yahoo | May 26, 2020

Coronavirus Vaccine Development Gathers Steam: 4 Winners

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

Yahoo | May 26, 2020

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to the COVID-19 pandemic. More than 88 percent of outstanding shares were represented at the meeting.

Yahoo | May 20, 2020

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

Yahoo | May 19, 2020

Read More 'AMGN' Stories Here

AMGN Price Returns

1-mo -4.26%
3-mo 12.98%
6-mo -3.18%
1-year 36.29%
3-year 58.81%
5-year 64.34%
YTD -5.73%
2019 27.60%
2018 15.23%
2017 22.27%
2016 -7.56%
2015 3.96%

AMGN Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full AMGN Dividend History

Continue Researching AMGN

Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:

Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.924 seconds.